Novartis

BMS, AstraZeneca, Novartis Add to 2024 M&A Upswing
BioSpace
Mon, 03/18/24 - 11:10 am
M&A
Bristol Myers Squibb
Novartis
AstraZeneca
Novo Nordisk
Pfizer
Novartis lays out $256M for antibody plant expansion in Singapore, plots 100 hires
Fierce Pharma
Sun, 03/17/24 - 09:27 pm
Novartis
Singapore
drug manufacturing
Novartis hits the cGAS, taking option to buy IFM unit for $90M upfront
Fierce Biotech
Wed, 03/13/24 - 10:40 am
Novartis
cGAS
IFM Therapeutics
Novartis' BTK inhibitor beats placebo in dermatology trial, lining up another potential indication
Fierce Biotech
Sun, 03/10/24 - 08:29 pm
Novartis
dermatology
Btk inhibitors
remibrutinib
hidradenitis suppurativa
clinical trials
Asthma Drug Xolair Now Indicated For Food Allergies: Next Challenge Is Insurer Coverage
Forbes
Wed, 03/6/24 - 11:25 am
Roche
Novartis
Xolair
insurers
food allergies
Novartis reports data from Phase IIIb trial of SMA therapy
Clinical Trials Arena
Tue, 03/5/24 - 11:15 am
Novartis
SMA
clinical trials
Zolgensma
Why is pharma going gaga for radiopharmaceuticals?
Pharmaphorum
Tue, 02/27/24 - 11:19 am
radiopharmaceuticals
oncology
Novartis
Eli Lilly
Bristol Myers Squibb
Roche's Xolair reduces reactions to severe food allergies in study
Reuters
Sun, 02/25/24 - 05:36 pm
Roche
Novartis
Xolair
clinical trials
food allergies
What did Big Pharma CEOs get paid in 2023?
Medical Marketing and Media
Fri, 02/23/24 - 10:22 am
Pharma CEOs
executive pay
AstraZeneca
Roche
Novartis
Novo, Novartis, BMS and J&J win judge's blessing to combine arguments in upcoming IRA hearing
Fierce Pharma
Wed, 02/21/24 - 11:25 am
Novo Nordisk
Novartis
JNJ
Bristol Myers Squibb
legal
Inflation Reduction Act
drug pricing
Novartis, zeroing in on innovative meds, launches strategic review of India outfit
Fierce Pharma
Sun, 02/18/24 - 08:36 pm
Novartis
India
FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies
Fierce Pharma
Sun, 02/18/24 - 08:31 pm
Roche
Novartis
Xolair
food allergies
FDA
Novartis CEO's 2023 pay rises 21% as Roche's helmsman nets $11M in his first year
Fierce Pharma
Mon, 02/5/24 - 11:16 pm
Novartis
Roche
Pharma CEOs
executive pay
Vas Narasimhan
Thomas Schinecker
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Novartis
M&A
MorphoSys
cancer
Amid CEO turmoil, Allarity loses rights to Novartis cancer drug over missed payments
Fierce Biotech
Fri, 02/2/24 - 11:57 am
Allarity Therapeutics
Novartis
kidney cancer
ovarian cancer
dovitinib
After Novartis' radiotherapy Pluvicto disappoints, CEO touts 'compelling case' for future growth
Fierce Pharma
Wed, 01/31/24 - 11:38 am
Novartis
earnings
Pharma CEOs
Vas Narasimhan
After GSK and Novartis handoffs, Laekna's drug fails ovarian cancer trial
Fierce Biotech
Mon, 01/29/24 - 10:27 pm
Laekna
afuresertib
clinical trials
ovarian cancer
GSK
Novartis
Incyte vets, with phase 1 within reach, raise $102M for new biotech to create better PARP, PI3K drugs
Fierce Biotech
Wed, 01/24/24 - 10:35 am
Synnovation Therapeutics
Incyte
AstraZeneca
GSK
Novartis
Pfizer
funding
cancer
PARP inhibitors
FDA requires 'boxed warning' for CAR-T cancer therapies
Reuters
Mon, 01/22/24 - 10:10 pm
CAR-T
FDA
warnings
Gilead Sciences
JNJ
Novartis
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors

Pages